期刊文献+

NF-κB活化及WT1、MDR1的表达在急性非淋巴细胞白血病中的临床意义 被引量:9

Clinical Significance of NF-κB Continual Activity and Expression of WT1 and MDR1 in Acute Nonlymphocytic Leukemia
下载PDF
导出
摘要 本研究通过观察初治与难治急性非淋巴细胞白血病中NF-κB活性及WT1、MDR1的表达水平,探讨三者在急性非淋巴细胞白血病疗效中的作用与相互关系,为寻找新的改善难治急性非淋巴细胞白血病疗效的方法提供理论依据。急性非淋巴性白血病患者45例,其中初治组20例(A组),难治组25例(分为B、C两组)。以15例单纯缺铁性贫血患者作为对照组。采用凝胶电泳迁移分析(EMSA)法检测各组病人NF-κB的活化水平,用逆转录多聚酶链式反应(RT-PCR)法检测各组病人WT1及MDR1的表达水平。结果发现,在对照组未检测到NF-κB活化及WT1和MDR1表达;在初治组中NF-κB的活化水平、WT1和MDR1表达水平均明显低于难治组,而在难治B、C两组中三者无明显区别;各组病人细胞中NF-κB活化水平与WT1及MDR1的表达水平呈正相关。结论:NF-κB的活化,WT1、MDR1的高表达可能是急性非淋巴细胞白血病难治的原因之一,急性非淋巴细胞白血病中NF-κB的活化水平与WT1、MDR1的表达呈正相关。 The study was aimed to explore the NF-κB continual activity and the expression of WT1 and MDR1 in acute non-lymphocytic leukemia (ANLL) patients, and to investigate if the three factors affect the curative effect of ANLL together as to provide some theoretical basis for finding new measures to improve the curative effect of refractory ANLL. The bone marrow samples of 45 ANLL patients was collected. 45 patients including 20 primary ANLL patients ( A group) and 25 refractory ANLL patients. Refractory ANLL patients were divided into 2 sub-groups (B, C groups). The primary patients who was no effect after more than two courses of treatment were taken as group B, and the patients with more than two relapses were taken as group C. At the same time , 15 patients with simple iron deficiency anemia were collected as negative control. The NF-κB continual activity was measured by using electrophoretic mobility shift assay(EMSA) and the expressions of WT1, MDR1 were detected by reverse transcriptase polymerase chain reaction (RT-PCR). The results showed that the activity of NF-κB and the expressions of WT1, MDR1 were not detected in 15 samples of simply iron deficiency anemia subjects. The NF-κB continual activity , the expression levels of WT1 and MDR1 in the refractory group were significantly higher than that in primary group (P 〈 0.001 ). But the NF-κB continual activity, the expression of WT1 gene and MDR1 gene were not significantly different between group B and group C (P 〉 0.05). By assaying the relativity between the them the NF-κB continual activity and the expression of WT1 or MDR1 had positive correlation in ANLL patients. It is concluded that the NF-κB continual activity, the overexpression of WT1 and MDR1 may be one of the reasons causing poor curative effect in acute non-lymphocytic leukemia. The NF-κB continual activity and the expression of WTI, MDR1, all show positive correlation in ANLL patients.
出处 《中国实验血液学杂志》 CAS CSCD 2007年第2期253-257,共5页 Journal of Experimental Hematology
关键词 NF—κB WT1 MDR1 急性非淋巴细胞白血病 NF-κB WT1 MDR1 acute non-lymphocytic leukemia
  • 相关文献

参考文献12

  • 1段卫明,陈子兴.WT1介导的转录调控通路与白血病[J].中国实验血液学杂志,2002,10(4):366-370. 被引量:5
  • 2张之南主编..血液病诊断及疗效标准 第2版[M].北京:科学出版社,1998:434.
  • 3邓家栋等主编..邓家栋临床血液学[M].上海:上海科学技术出版社,2001:1714.
  • 4EI-Sabban ME,Nasr R,Dbaibo G,et al.Arsenic-interferon-α-trigge red apoptosis in HTLV-transformed cells is associated with tax down regulation and reversal of NF-κB activation.Blood,2000; 96:2849-2855 被引量:1
  • 5Inoue K,Sugiyama H,Ogawa H,et al.WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.Blood,1994; 84:3071 -3079 被引量:1
  • 6O'Brien M,Kruh GD,Tew KD.The influence of coordinate overexpression of glutathione phase Ⅱ detoxification gene products on drug resistance.J Pharmacol Exp Ther,2000; 294:480-487 被引量:1
  • 7Kurz EU,Leader KB,Kroll DJ,et al.Modulation of human DNA topoisomerase Ⅰ alpha function by interaction with 14-3-3epsilon.J Biol Chem,2000; 275:13948-13954 被引量:1
  • 8Sugiyama H.Wilms' rumor gene WT1:its oncogenic function and clinical application.Int J Hematol,2001; 73:177-187 被引量:1
  • 9张宇红,李海民,窦科峰.核转录因子κB与肿瘤多药耐药的关系(文献综述)[J].国外医学(外科学分册),2004,31(2):95-98. 被引量:10
  • 10Bentires-Alj M,Barbu V,Fillet M,et al.NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells.Oncogene,2003; 22:90-97 被引量:1

二级参考文献49

  • 1Kuo MT, et al. Oncogene 2002; 21(13): 1945-1954. 被引量:1
  • 2Ros JE, et al. Hepatology 2001; 33(6): 1425 - 1431. 被引量:1
  • 3Thevenod F, et al.Biol Chem 2000; 275(3) : 1887 - 1896. 被引量:1
  • 4Pham LV, et al. Immunology 2002; 171(1): 88-95. 被引量:1
  • 5Ueda M, et al. Cancer Lett 2003; 193(2): 177-182. 被引量:1
  • 6Chiao PJ, et al. Cancer 21302; 95(8) : 1696- 1705. 被引量:1
  • 7Cheng Q, et al. Oncogene 2000; 19(42): 4936- 4940. 被引量:1
  • 8Wang CY, et al. Science 1998; 281(5383): 1680- 1683. 被引量:1
  • 9Kawashima T, et al. Immunology. 2001; 167(7): 3652-3660. 被引量:1
  • 10Tumang JR, et al. Cell Immunol 2002; 217( 1-2): 47-57. 被引量:1

共引文献13

同被引文献49

引证文献9

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部